Dr. Kwa on the TAILORx Trial in Breast Cancer

Maryann J. Kwa, MD
Published: Thursday, Jul 05, 2018



Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Findings from the phase III TAILORx trial were presented at the 2018 ASCO Annual Meeting. The study examined intermediate-risk patients with hormone receptor-positive, HER2-negative, node-negative, early-stage breast cancer based on the 21-gene recurrence score. These were patients who had an Oncotype DX Breast Recurrence Score test of 16 to 25. Half of patients were randomized to receive chemotherapy and endocrine therapy and half were randomized to receive endocrine therapy alone. The study found that there was no difference in disease-free survival between groups, said Kwa.

The noninferiority of endocrine therapy alone compared with endocrine therapy and chemotherapy (HR, 1.08; 95% CI, 0.94-1.24; P = .26) met the trial’s primary endpoint.

However, Kwa notes that a subgroup analysis that looked at women who were 58 years of age or younger found a small benefit with chemotherapy and endocrine therapy.
SELECTED
LANGUAGE


Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Findings from the phase III TAILORx trial were presented at the 2018 ASCO Annual Meeting. The study examined intermediate-risk patients with hormone receptor-positive, HER2-negative, node-negative, early-stage breast cancer based on the 21-gene recurrence score. These were patients who had an Oncotype DX Breast Recurrence Score test of 16 to 25. Half of patients were randomized to receive chemotherapy and endocrine therapy and half were randomized to receive endocrine therapy alone. The study found that there was no difference in disease-free survival between groups, said Kwa.

The noninferiority of endocrine therapy alone compared with endocrine therapy and chemotherapy (HR, 1.08; 95% CI, 0.94-1.24; P = .26) met the trial’s primary endpoint.

However, Kwa notes that a subgroup analysis that looked at women who were 58 years of age or younger found a small benefit with chemotherapy and endocrine therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication
x